AI In Market Research Is Meaningless Unless It Changes Commercial Outcomes

There is a growing narrative that the market research industry is broken. Too slow, too traditional, too inefficient to meet modern demands. According to this view, AI must overhaul the discipline from the ground up, a storyline that technology firms have understandably been keen to reinforce.

Yet at the recent PMRC (Pharmaceutical Marketing Research Conference) in New Jersey, during a panel on boardroom-level transformation, a senior insights leader offered a very different perspective. Across more than 700 pharmaceutical research studies he had commissioned during his career, only one had failed. Every other study had done what it was meant to do - it answered the key business question.

The discussion reflected a quiet frustration that much of the AI progress so far has centered  on operational efficiency. Faster synthesis of qualitative data. Automated analysis. Synthetic respondents. All helpful improvements, but none clearly demonstrating that commercial outcomes are stronger than they were before. If research is not fundamentally ineffective, then AI cannot be positioned as the savior.

The real pressure point is elsewhere. Commercial environments are becoming more complex. Decision cycles are shortening. Competitive landscapes are more volatile. In pharma alone, the cost of launching a new medicine can run into hundreds of millions and small shifts in uptake can translate into significant lifetime revenue differences. In that context, AI has to prove its value by strengthening decisions, not just speeding up processes.

AI Should Change Decisions, Not Just Processes

Its contribution should be visible in at least one of four ways. It should enable:

• Better decisions
• Earlier decisions
• Bolder decisions
• More confident decisions

If it does not shift one of those levers, it may improve workflow, but it does not meaningfully improve business performance.

In pharma, that means shaping launch strategy, targeting, activation and resource allocation in ways that genuinely influence uptake.

Here are three practical ways this can happen.

1. Collapsing Insight and Strategy in Patient Journey Work

Traditionally, patient journey research diagnoses friction points and unmet needs. Strategy follows later.

AI allows organizations to go further before fieldwork even begins. By integrating prior studies, behavioral frameworks and treatment pathway data, it is possible to map likely journey pain points by market and generate potential intervention territories alongside them.

Research then becomes a process of validating and refining solutions with clinicians, rather than simply documenting problems. The output is not just insight, but prioritized and commercially grounded actions. The discussion shifts from “What is broken?” to “What should we implement, and where should we invest?”

2. Upgrading Concept Testing Through Meta-Analysis

Concept testing is often conducted as a standalone exercise. Stimuli are evaluated, scores compared and a preferred route selected. What is frequently missing is cumulative learning.

By combining robust creative evaluation frameworks with historic insight databases and behavioral models, AI can analyze patterns across multiple past studies to identify which types of messages, mechanisms and emotional triggers have consistently translated into behavioral change.

New concepts can then be assessed not only on how they perform in isolation, but on how well they align with proven drivers of effectiveness. The commercial benefit is that fewer resources are committed to ideas that generate interest but fail to convert and greater investment is placed behind concepts with stronger evidence for real-world impact.

3. Turning Static Segments Into Living Commercial Systems

Segmentation often starts as a strategic exercise but becomes static in execution. Once healthcare professionals are typed into segments, engagement strategies can remain fixed even as behavior shifts.

AI makes it possible to layer dynamic personas onto existing segment structures and update them using prescribing data, CRM inputs and market changes. The segment remains stable, but the commercial posture evolves.

This enables messaging, field force effort and budget allocation to adjust in line with where a customer actually sits in their adoption journey. Segmentation moves from descriptive taxonomy to active commercial system.

The Real Test

In each of these cases, the evaluation standard is clear. Does this approach change a strategic choice? Does it redirect investment? Does it increase the probability of uptake?

If the answer is no, then the application may be technically impressive, but it is not commercially meaningful.

Market research has shaped high-stakes decisions for decades and consistently reduced risk for organizations. It does not need rescuing. But it does need to higher the bar for commercial impact.

AI earns its place when it sharpens judgement, closes the gap between insight and action and increases the likelihood that brands succeed in market. If progress is measured purely in hours saved, the result will be better process. If it is measured in commercial impact, the result will be better outcomes.